Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protein in 'good cholesterol' may be a key to treating pulmonary hypertension

28.08.2014

Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis.

A new study at UCLA demonstrates that they may also contribute to pulmonary hypertension, a serious lung disease that narrows the small blood vessels in the lungs.


This images shows the differences in the structure of a small lung artery (top row) and heart cross section (lower row) of rodents without disease (far left column); with pulmonary hypertension (middle) and a diseased rodent (left) treated with the HDL peptide. Note the very narrowed lung artery, and thick walls and larger chamber of the right heart in the diseased animal and improvements with 4F peptide treatment.

Credit: UCLA


This image shows the differences in the structure of a small lung artery (top row) and heart (lower row) of rodents without disease (far left column); with pulmonary hypertension (middle) and a diseased rodent (right) treated with the molecule microRNA193. Note the very narrowed lung artery, and thick walls and larger chamber of the heart in the diseased animal and improvements with microRNA-193 treatment.

Credit: UCLA

Using a rodent model, the researchers showed that a peptide mimicking part of the main protein in high-density lipoprotein (HDL), the so-called "good" cholesterol, may help reduce the production of oxidized lipids in pulmonary hypertension. They also found that reducing the amount of oxidized lipids improved the rodents' heart and lung function.

The study appears in the current online edition of the peer-reviewed journal Circulation.

A rare progressive condition, pulmonary hypertension can affect people of all ages. The disease makes it harder for the heart to pump blood through these vital organs, which can lead to heart failure.

"Our research helps unravel the mechanisms involved in the development of pulmonary hypertension," said Dr. Mansoureh Eghbali, the study's senior author and an associate professor of anesthesiology at the David Geffen School of Medicine at UCLA. "A key peptide related to HDL cholesterol that can help reduce these oxidized lipids may provide a new target for treatment development."

Lipids such as fatty acids become oxidized when they are exposed to free radicals — tiny particles that are produced when the body converts food into energy -- or when they are exposed to pollution, and in numerous other ways.

Although researchers have known that oxidized lipids played a role in the development of atherosclerosis and other vascular diseases, the UCLA team discovered higher-than-normal levels of oxidized proteins in rodents with pulmonary hypertension.

The UCLA researchers also knew that apoA-1, a protein that is a key component of HDL cholesterol, can reduce oxidized lipids, so they used a small peptide called 4F that mimics the action of apoA-1 and found that the 4F not only decreased the levels of oxidized lipids in the rodents, but also improved their heart and lung function. Specifically, the peptide restored the altered expression of a key molecule called micro ribonucleic acid (microRNA-193), which targets the action of essential enzymes involved in the production of oxidized lipids.

"The increased amounts of these oxidized lipids due to pulmonary hypertension keeps the expression of this molecule under check, which aggravates symptoms of the disease," said first author Dr. Salil Sharma, a UCLA postdoctoral researcher in anesthesiology.

By restoring the expression of microRNA-193 to its full potential, the researchers reduced the amount of oxidized lipids in the animals with pulmonary hypertension.

One of the hallmarks of pulmonary hypertension is a proliferation of smooth muscle cells in the lungs, which is harmful because it narrows the lungs' small blood vessels.

Additionally, Eghbali's team found reduced levels of microRNA-193 in the blood and lung tissue of human patients with the disease and discovered that they could slow the proliferation of the smooth muscle cells by increasing levels of microRNA-193 in the cells that had been isolated from these patients' lungs.

Further research will be required to test the potential of the HDL-related peptide and microRNA-193 in human disease, and to better understand how the levels of oxidized lipids in the blood may correlate to disease severity in people with pulmonary arterial hypertension.

###

The study was funded in part by the American Heart Association, the National Institute of Health, the UCLA Clinical and Translational Science Institute and the Iris Cantor–UCLA Women's Health Center executive advisory board.

The study's other authors were Dr. Soban Umar, Andrea Iorga, Gabriel Wong, Denise Mai and Dr. Kaveh Navab of the division of molecular medicine at UCLA's department of anesthesiology; David Meriwether, Dr. Mohamad Navab, Dr. Alan Fogelman and Dr. Srinivasa Reddy of the division of cardiology at UCLA's department of medicine; Dr. David Ross of the division of pulmonary critical care medicine at the David Geffen School of Medicine at UCLA's department of medicine; and Francois Potus, Sandra Breuils-Bonnet, Dr. Steve Provencher and Dr. Sébastien Bonnet of Laval University in Québec, Canada.

All of the intellectual property for the HDL-related peptide is owned by the University of California Regents and managed by the UCLA Office of Intellectual Property and Industry Sponsored Research. The technology is currently licensed exclusively to Bruin Pharma Inc. Fogelman, Navab and Reddy are principals in Bruin Pharma, and Fogelman is an officer in the company. Other disclosures are listed in the manuscript.

Rachel Champeau | Eurek Alert!
Further information:
http://www.uclahealth.org/

Further reports about: HDL Health Medicine Protein UCLA blood cholesterol hypertension lung pulmonary

More articles from Health and Medicine:

nachricht Cotton fibres instead of carbon nanotubes
07.05.2015 | Schweizerischer Nationalfonds SNF

nachricht Stanford researchers observe the moment when a mind is changed
06.05.2015 | Stanford School of Engineering

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Spray drying the precision particle under the virtual magnifying glass

Spray drying is a common manufacturing process, used in the production of ceramic granulate for technical components or dental prostheses as well as dissolvable medicinal substances, food additives and in the processing of milk into powder. Using computer simulation methodology developed by scientists at the Fraunhofer Institute for Mechanics of Materials IWM, a more comprehensible understanding can now be gained of the behavior of particles in solvent during the spray drying process. This allows powder and granulate manufacturers to specifically adjust the properties of their products while reducing waste.

Previously, it was unusual for granule and powder producers to use granulation simulations to improve their products. For new product development or process...

Im Focus: The random raman laser: A new light source for the microcosmos

Texas A&M University researchers demonstrate how a narrow-band strobe light source for speckle-free imaging has the potential to reveal microscopic forms of life

In modern microscope imaging techniques, lasers are used as light sources because they can deliver fast pulsed and extremely high-intensity radiation to a...

Im Focus: Pulsar with widest orbit ever detected

Discovered by high school research team

A team of highly determined high school students discovered a never-before-seen pulsar by painstakingly analyzing data from the National Science Foundation's...

Im Focus: Erosion, landslides and monsoon across the Himalaya

Scientists from Nepal, Switzerland and Germany was now able to show how erosion processes caused by the monsoon are mirrored in the sediment load of a river crossing the Himalaya.

In these days, it was again tragically demonstrated that the Himalayas are one of the most active geodynamic regions of the world. Landslides belong to the...

Im Focus: Through the galaxy by taxi - The Dream Chaser Space Utility Vehicle

A world-class prime systems integrator and electronic systems provider known for its rapid, innovative, and agile technology solutions, Sierra Nevada Corporation (SNC) is currently developing a new space transportation system called the Dream Chaser.

The ultimate aim is to construct a multi-mission-capable space utility vehicle, while accelerating the overall development process for this critical capability...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Green Summit 2015: the summit of the essential

05.05.2015 | Event News

HHL Energy Conference on May 11/12, 2015: Students Discuss about Decentralized Energy

23.04.2015 | Event News

“Developing our cities, preserving our planet”: Nobel Laureates gather for the first time in Asia

23.04.2015 | Event News

 
Latest News

Institutions of higher education spent more than Euro 46 billion in 2013

07.05.2015 | Statistics

Cotton fibres instead of carbon nanotubes

07.05.2015 | Health and Medicine

Expedition Genomics Lab: the mobile revolution in genetic analysis

06.05.2015 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>